Preliminary results of a small-scale trial in which the first and second doses of COVID-19 vaccines of Sputnik V and AstraZeneca were administered have revealed that the practice offered significant protection against the disease and posed no risk of adverse side effects.
In an official statement, the Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund which is responsible for Sputnik V’s international marketing, said the trial involved 50 volunteers and was held in Azerbaijan.
RDIF will publish the detailed results of the trial, including the data on the immune response generated by combining both vaccines, next month.
the Russian government also approved the large-scale clinical trials of combining the Russian and British vaccines that will be held in five locations in the country.
